Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact

Current Oncology

View Publication Info
 
 
Field Value
 
Title Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact
 
Creator Johnston, K.M.
Sheffield, B.S.
Yip, S.
Lakzadeh, P.
Qian, C.
Nam, J.
 
Subject Foundation Medicine
health and budget impact analysis
genomic profiling
next generation sequencing
non-small cell lung cancer
single-gene tests
hotspot panel
Canadian private payer
 
Description Background Single-gene tests and hotspot panels targeting specific subsets of biomarkers constitute the Canadian genomic testing landscape for non-small-cell lung cancer (nsclc). However, newer testing options such as compre­hensive genomic profiling (cgp) offer improved detection rates and identification of multiple classes of genomic alterations in a single assay, minimizing tissue requirements and turnaround time. The objective of the present analysis was to assess the health and budget impacts of adopting cgp testing for nsclc in Canada.
Methods This study assessed the impact of funding the cgp tests FoundationOne CDx and FoundationOne Liquid (Foundation Medicine, Cambridge, MA, U.S.A.) over a 3-year time horizon using a Canadian societal perspective for Ontario. Conventional testing strategies were summarized into two reference scenarios: a series of single-gene tests only, and reflex single-gene testing followed by a hotspot panel for negative results. Four adoption scenarios for cgp testing were considered: replacing all single-gene and hotspot panel testing, replacing hotspot panel testing only, use after negative single-gene and hotspot testing, and use of FoundationOne Liquid in individuals with insufficient tissue for conventional testing.
Results When cgp testing was assumed to replace all conventional testing with 50% uptake, the budget impact per person per year ranged from $0.71 to $0.87, depending on the reference scenario, with a 3-year gain of 680.9 life–years and 3831 working days over the full cohort.
Conclusions Given the present testing landscape for patients with nsclc in Canada, listing cgp testing could opti­mize the selection of appropriately targeted treatments, and thus add life–years and productivity for this population, with a minimal budget impact.
 
Publisher Multimed Inc.
 
Date 2020-08-13
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/5995
10.3747/co.27.5995
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/5995/9637
http://www.current-oncology.com/index.php/oncology/article/view/5995/9531
http://www.current-oncology.com/index.php/oncology/article/view/5995/9699
 
Rights Copyright (c) 2020 Current Oncology
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library